Shen et al.263 recognized that GC patients carrying MET G1163R or D1228Y/N mutations are likely to show resistance to the TKI drug crizotinib, whereas patients with MET V1092L, D1228G, or Y1230H mutations could benefit from this targeted therapy. This evidence concerns the gene MET and gastric cancer.